No significant differences were observed in the percentage of CD19+/CD5+/TLR2+ (median: CLL 0.38%; healthy volunteers (HV) 1.58%) (within CD19+/CD5+ cells) and CD19+/CD5−/TLR2+ (within CD19+/CD5− cells) (median: CLL 0.41%; HV 1.94%) (p > 0.05). The gene discussed is TLR2; the disease is B-cell chronic lymphocytic leukemia.